← Leaderboards
Amber Simpson
Sloan-Kettering Inst Can Research
$1,284,179
Attributed
$3,726,841
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $934.5K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,726,841 · 1
By mechanism
R01$3,726,841 · 1
Top collaborators
- Richard Kinh Gian Do6 shared
- Yun Shin Chun5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- William Robert Jarnagin$4,049,789
- Richard Kinh Gian Do$1,284,179
- Yun Shin Chun$1,158,484
- Andrea Cercek$4,410,417
- Harini Veeraraghavan$2,433,388
Others in their field
Other Emerging Leaders on “Response Biomarker”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$155,963,408
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan M Landau · University Of California Berkeley$47,252,026
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
Research focus
Response BiomarkerMetastatic Neoplasm To The LiverInstitutionRecurrenceColon Cancer PatientsPrognosticEnsureInnovationPersonalized MedicineRadiomicsUnited StatesValidationPublicationsCancer CenterAlgorithmsColorectal CancerColorectalImaging BiomarkerMalignant NeoplasmsCancer CareBaseConvolutional Neural NetworkAffectCost
Grant awards (6)
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$659,173
R01 · FY2023 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$683,138
R01 · FY2022 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$251,390
R01 · FY2022 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$690,882
R01 · FY2021 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$698,152
R01 · FY2020 · CA
Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases$744,106
R01 · FY2019 · CA